WuXi Biologics Included in Hang Seng ESG 50 Index

Core Insights - WuXi Biologics has been included in the Hang Seng ESG 50 Index, marking it as the only pharmaceutical company selected this year [1] - The Hang Seng ESG 50 Index, launched in 2020, aims to highlight the top 50 ESG leaders with high market capitalization in Hong Kong [2] - WuXi Biologics received an "A" rating in the 2024 HKQAA Sustainability Ratings, placing it in the top 10% among industry peers [3] Company Achievements - The CEO of WuXi Biologics expressed satisfaction with the inclusion in the Hang Seng ESG 50 Index, emphasizing the company's commitment to enhancing ESG capabilities [4] - WuXi Biologics is a signatory to the United Nations Global Compact and the Science Based Targets initiative (SBTi), demonstrating its commitment to sustainable development [4] - The company has received multiple recognitions from ESG rating agencies, including an "AAA" rating from MSCI ESG Ratings and a Platinum Medal from EcoVadis [5] Operational Overview - WuXi Biologics operates as a leading global Contract Research, Development and Manufacturing Organization (CRDMO), providing end-to-end solutions for biologics [6] - The company employs over 12,000 skilled workers across various countries and supports 742 integrated client projects as of June 30, 2024 [7] - WuXi Biologics integrates ESG responsibilities into its business strategy, utilizing next-generation biomanufacturing technologies and clean energy sources [8]